96 week results from the MONET trial: A randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with hiv RNA <50 copies/ml at baseline

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1878-1885

  Clumeck, Nathan ^a   Rieger, Armin ^b   Banhegyi, Denes ^c   Schmidt, Wolfgang ^d   Hill, Andrew ^e   van Delft, Yvonne ^f   Moecklinghoff, Christiane ^g   Arribas, Jose ^h  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF VIENNA   (Austria)

^c I Belgyogyaszati Osztaly   (Hungary)

^d Praxis   (Germany)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f Janssen EMEA   (Netherlands)

^g Janssen EMEA   (Germany)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Clinical trials; HIV drug resistance; Protease inhibitor monotherapy; Renal adverse events

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; HEMOGLOBIN; LAMIVUDINE; LOPINAVIR; LOW DENSITY LIPOPROTEIN; RITONAVIR; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GLUCOSURIA; HEMATURIA; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIXED INFECTION; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OPTICAL DENSITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SIDE EFFECT; TREATMENT DURATION; URINALYSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; MALE; NUCLEOSIDES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT FAILURE;

EID: 79960441308     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr199     Document Type: Article

References (21)

1. Hammer S, Eron J, Reiss P et al. Antiretroviral treatment of adult HIV infection. 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.
2. European AIDS Clinical Society (EACS). Guidelines for the Clinical Management of HIV Infected Adults in Europe. http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf (1 September 2010, date last accessed).
3. Arribas J, Horban A, Gerstoft J et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mL. AIDS 2010; 24: 223-30.
4. Katlama C, Valentin MA, Algarte-Genin M et al. Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS 2010; 24: 2365-74.
5. Hirsch M, Gunthard H, Schapiro J et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47: 266-85.
6. DAIDS 2004. Division of AIDS Table for Grading the Severity of Adult and Paediatric Adverse Events. http://rsc.tech-res.com/safetyandpharmacovigilance/ (1 April 2011, date last accessed).
7. Hill A, Sabin S. Designing and interpreting HIV non-inferiority trials in naïve and experienced patients. AIDS 2008; 22: 913-21.
8. US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research. Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements- Clinical Considerations for Accelerated and Traditional Approval. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf (1 April 2011, date last accessed).
9. Phillips AN, Walker S. Drug switching and virologic based endpoints in trials of antiretroviral drugs for HIV infection. AIDS 2004; 18: 365-70.
10. Hill A, van Delft Y, Moecklinghoff C. Correlation between laboratory parameters and use or discontinuation of nucleoside analogues in the MONET trial. In: Abstracts of the Eleventh Workshop on Adverse Drug Reactions and co-Morbidities in HIV, Philadelphia, USA, October 2009. Abstract 23, p. A44. International Medical Press, London, UK.
11. Nelson M, Mohammed P, Hill A et al. Hepatitis laboratory parameters in the MONET trial: association with hepatitis C co-infection. In: Abstracts of the World AIDS Conference, Vienna, Austria, July 2010. Abstract WEPE0146. International AIDS Society, Geneva, Switzerland.
12. US Department for Health and Social Security. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, January 10th 2011. http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7 (1 March 2011, date last accessed).
13. Ribaudo H, Smith K, Robbins G et al. Race differences in the efficacy of initial ART on HIV infection in randomized trials undertaken by ACTG. In: Abstracts of the Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, February 2011. Abstract 50, p. 89. Conference on Retroviruses and Opportunistic Infections, Alexandria, VA, USA.
14. Domingo P, Lazzarin A, Ballesteros J et al. 96-week analysis of the tolerability of darunavir/ritonavir once daily versus lopinavir/ritonavir in treatment-naïve patients co-infected with hepatitis B and/or C in the ARTEMIS trial. In: Abstracts of the Fifth International Workshop on HIV and Hepatitis co-infection, Lisbon, Portugal, June 2009. Abstract P-52. Virology Education, Utrecht, The Netherlands.
15. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
16. Gupta R, Hill A, Sawyer A et al. Emergence of drug resistance in HIV Type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47: 712-22.
17. Lennox J, DeJesus E, Lazzarin A et al. Raltegravir demonstrates durable efficacy through 96 weeks: results from STARTMRK, a Phase III study of raltegravir-based versus efavirenz-based therapy in treatment naïve patients. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, USA, September 2009. Abstract H-924b. American Society for Microbiology, Washington, DC, USA.
18. Yilmaz A, Izadkhashti A, Price R et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1 infected adults. AIDS Res Hum Retroviruses 2009; 25: 1-5.
19. Horberg M, Tang B, Towner W et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naïve patients. J Acquir Immune Defic Syndr 2010; 53: 62-9.
20. Kirk O, Mocroft A, Reiss P et al. Chronic kidney disease and exposure to ART in a large cohort with long-term follow-up: the EuroSIDA study. In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, 2010. Abstract 107LB, p. 110. Conference on Retroviruses and Opportunistic Infections, Alexandria, VA, USA.
21. Valantin M, Flandre P, Kolta S et al. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with CDRV/r monotherapy vs 2 NRTI+DRV/r in the MONOI-ANRS 136 randomized trial: results at 48 weeks. In: Abstracts of the Eighteenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, February 2010. Abstract 721. Conference on Retroviruses and Opportunistic Infections, Alexandria, VA, USA.